Obesity Management Market

Obesity management sales will strengthen through 2036, anchored by pharmacotherapy at 74.0% of treatment-type revenue in 2026. Injectable therapies account for 72.0% of route-of-administration revenue in 2026. The market is projected to increase from USD 42.5 billion in 2026 to USD 133.0 billion by 2036. GLP-1 receptor agonists account for the largest revenue pool.